5 Reasons Why Celgene Should Buy Competitor Biogen
There are several reasons why Celgene should buy Biogen.
Should Celgene (CELG) - Get Report buy Biogen (BIIB) - Get Report ? The Street's Adam Feuerstein thinks so, and offered several reasons why the deal makes sense.
Feuerstein said Celegene would benefit from Biogen's multiple sclerosis drug franchise, and would also get a head start on drugs for neurodegenerative diseases. Acquiring Biogen would also give Celgene the orphan drug Spinraza, as well access to Biogen's development of biologics.
Feuerstein believes a deal between the two would be transformative, and puts the potential deal value at $75 billion to $85 billion.
